By otakuyassine3@gmail.com 
Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) – Stock analysts at Zacks Research dropped their Q1 2025 EPS estimates for Charles River Laboratories International in a note issued to investors on Thursday, April 10th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $2.06 for the quarter, down from their previous estimate of $2.07. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q2 2025 earnings at $2.29 EPS, Q3 2025 earnings at $2.40 EPS, Q4 2025 earnings at $2.55 EPS, FY2025 earnings at $9.30 EPS, Q1 2026 earnings at $2.44 EPS, Q3 2026 earnings at $2.65 EPS, Q4 2026 earnings at $2.68 EPS, FY2026 earnings at $10.22 EPS, Q1 2027 earnings at $2.65 EPS and FY2027 earnings at $10.91 EPS.
A number of other analysts have also recently commented on CRL. Morgan Stanley cut their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. Mizuho cut their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a research note on Wednesday. JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, Barclays reduced their price target on Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $182.00.
Check Out Our Latest Analysis on CRL
Charles River Laboratories International Stock Performance
Shares of CRL stock opened at $99.56 on Friday. The company has a market capitalization of $4.89 billion, a P/E ratio of 663.71, a P/E/G ratio of 4.54 and a beta of 1.45. The business’s 50 day moving average is $156.71 and its two-hundred day moving average is $177.01. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $254.15.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period last year, the firm earned $2.46 EPS. The company’s quarterly revenue was down 1.1% on a year-over-year basis.
Insider Buying and Selling
In related news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CRL. Versant Capital Management Inc boosted its position in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the period. Rothschild Investment LLC raised its stake in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 144 shares in the last quarter. Pinnacle Bancorp Inc. boosted its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Optiver Holding B.V. purchased a new position in Charles River Laboratories International in the fourth quarter valued at $37,000. Finally, GeoWealth Management LLC grew its stake in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after purchasing an additional 190 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Further Reading
Receive News & Ratings for Charles River Laboratories International Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Charles River Laboratories International and related companies with MarketBeat.com’s FREE daily email newsletter.